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Abstract 
Interferon a (IFN) is important for anti-viral defense. IFN binds to cell surface receptors 
and stimulates the Janus kinase-signal transducer and activator of transcription 
(Jak/ST AT) pathway which activates transcription of anti -viral effector genes 2' ,5 '-
oligoadenylate synthetase (OAS), myxovirus resistance gene 1 (Mx1), and double-
stranded RNA-dependent protein kinase (PKR). Upon virus infection, viral double 
stranded RNA (dsRNA) activates the OAS/latent ribonuclease (RNase L) pathway which 
degrades viral RNA whereas the PKR/eiF2a pathway blocks translation of viral RNA. 
Mx1 has been shown to be involved in blockage of viral nucleocapsid transport or viral 
RNA synthesis. Previously, we demonstrated that activation ofthe Ras/Raf/MEK 
pathway inhibits IFN-induced anti-viral responses. The objective of this study was to 
determine how activated Ras/Raf/MEK pathway suppresses IFN-induced responses. 
First, we stimulated vector control NIH 3T3 cells (BABE) and Ras transformed NIH 3T3 
cells (RasV12) with IFN and then examined mRNA expression levels ofOAS, Mx1, and 
PKR mRNA at 6 and 12 hours after the stimulation. We found that OAS, Mx1, PKR 
mRNA expression were higher in BABE compared to RasV12. We were able to rescue 
Mx1 and OAS gene expression induced by IFN in RasV12 by treatment ofU0126, a 
specific inhibitor ofMEK. Similarly, western blot analysis revealed that OAS protein 
levels were restored in RasV12 stimulated with IFN using U0126 and RNA interference 
(RNAi) to Ras. To further determine how activated Ras/Raf/MEK pathway suppresses 
IFN-induced gene transcription, we investigated activation status of the Jak/STAT 
pathway in IFN stimulated BABE and RasV12 by Western blot analysis using antibodies 
against phosphorylated STATl, total STATl, phosphorylated STAT2 and total STAT2. 
As a result, we observed higher phosphorylation and total levels of STATl and STAT2 in 
BABE compared to RasV12. When treated with U0126, phosphorylation ofboth STAT 
proteins was restored in RasV12. These results suggest that activated Ras/Raf/MEK 
pathway inhibits activation of the JAK/STAT pathway leading to suppression ofiFN-
induced gene transcription. 
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Chapter 1: Introduction 
1.1 Interferons 
The interferon (IFN) system is important for early anti-viral defense (Samuel, 
2001). When infected by viruses, cells respond by releasing IFNs which bind to cellular 
receptors and activate an intracellular anti-viral state to protect the host from viral 
infection. Discovered in 1957, IFNs were given their name due to their ability to interfere 
with viral replication (Issacs and Lindenmann, 1957). Since their discovery, IFNs have 
been shown to be involved in several cellular functions other than anti-viral defense 
including proliferation and activation of immune cells. Classification ofiFNs is based on 
the surface receptors which they interact with and on sequence homology (Malmgaard, 
2004). Within the IFN superfamily, IFNs are classified into three different types, type I, 
II, or III. 
1.1.1 Type I IFNs 
Type I IFNs consist of a number of different members including IFNa, IFNp, 
IFN't, and IFNro. In humans, all type I IFN genes are located on chromosome 9 whereas 
in mice, these genes are clustered on chromosome 4 (Samuel, 2001). There are several 
different subtypes ofiFNa and IFN't whereas IFNP and IFNro are both unique cytokines 
each encoded by a single gene. All cell types possess the ability to produce type I IFN s in 
response to viral infection. In virus infected cells, the ratio ofiFNa, IFNp, and IFNro 
production depends upon several factors such as host cell type, the species of organism, 
and type of virus (Pestka eta!, 2004). All type I IFNs bind with the same surface 
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receptor, IFNa. receptor (IFNAR), which is comprised of two subunits IFNARl and 
IFNAR2, to mediate a wide breadth of cellular functions (Samuel, 2001). The biological 
activities of type I IFNs include anti-viral defense (Van den Brocket al, 1995), inhibition 
of proliferation (Clemens, 2003), activation of natural killer cells and lymphocytes 
(Ortaldo et al, 1983), regulation of major histocompatibility complex (MHC) class I 
antigen expression (Do lei et a/, 1983 ), and suppression of angiogenesis (Kerbel and 
Folkman, 2002). 
1.1.2 Type II IFN 
Type II IFN consists of only one member, IFNy, which is a cytokine also 
important for mediation of anti-viral responses (Costa-Pereira et al, 2002). Production of 
IFNy occurs during later stages of viral infection where it also has an important role in 
regulating adaptive immune responses (Pestka eta/, 2004). IFNy initiates cellular 
signalling events by binding with surface receptors interferon y receptor 1 (IFNGR1) and 
2 (IFNGR2). IFNy is involved in upregulating the transcription of about 1300 genes 
whereas IFNa. and p regulate transcriptional control of 100-300 genes (MacMicking, 
2004). Only certain immune cells are able to synthesize IFNy, including natural killer 
(NK) cells, CD8 and CD4 cells (Costa-Pereira et al, 2002). Effector functions of IFNy 
include differentiation of CD4 cells, macrophage activation, and anti-viral defense 
(Pestka et al, 2004). 
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1.1.3 Type III IFN 
The type III interferon (IFN) family consists ofiFN-).1, -A2 and -.\3 which are also 
referred to as interleukin-29 (IL-29), IL-28A, and IL-28B respectively. Although type III 
IFNs bind to a unique receptor, they share many functional characteristics with type I 
IFN s. Both type I and type III IFN s are induced by viral double-stranded RNA, transduce 
signals to the nucleus via the Janus kinase-signal transducer and activator of transcription 
(Jak-STAT) pathway, activate interferon stimulated response element (ISRE) regulated 
gene expression and upregulate MHC class I antigen expression. In addition, cells treated 
with type III IFNs are resistant to viral infection (Kotenko et al, 2003; Sheppard et al, 
2003). A recent study has demonstrated that type III IFNs also possess potent anti-viral 
and immunostimulatory activity in vivo (Bartlett et al, 2005). 
1.2 Induction and transcriptional control of type I IFNs 
The mechanism of induction oftype I IFNs during viral infection is a complex 
molecular system involving both viral components and host cell proteins. Two major 
pathways which regulate induction ofiFN include (1) retinoic acid gene I (RIGI)-
dependant pathway and (2) Toll-like receptor (TLR)-dependent pathway. 
1.2.1 The RIGI-dependent pathway 
RIGI is an intracellular receptor capable of binding to viral double stranded 
(dsRNA) or synthetic dsRNA (poly (I:C)), and has recently been identified as an 
important inducer ofiFNa and p (Figure 1) (Yoneyama et al, 2004). RIGI consists of a 
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C-terminal RNA helicase domain which is capable of binding with dsRNA and anN-
terminal caspase recruitment domain (CARD). Interaction of the helicase domain with 
viral dsRNA induces a conformational change ofRIGI that promotes interactions 
between RIGI and CARD and downstream CARD-containing adaptor proteins (Honda et 
al, 2005). Recent studies have identified mitochondrial anti-viral signalling protein 
(MAVS) as an important downstream adaptor protein in RIGI signalling (Seth et al, 
2005). Upon activation by RIGI, MAVS phosphorylates TANK-binding kinase 1 
. (TBK1), and inducible IxB kinase (IKKE/i) which in turn phosphorylate interferon 
regulatory factor 3 (IRF3) and 7 (IRF7). Once activated, IRF3 and IRF7 translocate into 
the nucleus to activate transcription ofiFNa and IFN~ (Takaoka and Yanai, 2006). The 
regulatory role ofRIGI in the induction ofiFN was confirmed in mouse knockout studies 
in which loss ofRIGI resulted in inhibition ofiRF3 activation (Kato et al, 2005). 
IRF3 and IRF7 are constitutively expressed and in their inactive forms, are 
localized within the cytoplasm (Au et al, 1995). Upon phosphorylation, IRF3 dimerizes 
and translocates into the nucleus where it forms a complex with CRE-binding protein 
(CREB) and p300 to activate transcription of target genes (Juang et al, 1998). 
Dimerization of IRF7 also occurs upon its phosphorylation, followed by translocation into 
the nucleus and binding to promoter elements of the IFN genes. However, it has been 
shown that IRF3 activation is more important for transcription ofiFN~ rather than IFNa 
genes, whereas IRF7 causes activation of both IFNa and IFNI3 (Sato et al, 2000). IRF5 is 
also involved in both the induction and suppression of IFN expression. As with IRF3 and 
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Figure 1. Induction ofiFNa/f3 via the RIGI-dependent pathway. The C-terminal helicase 
domain ofRIGI binds intracellular viral dsRNA to activate theN-terminal CARD 
domains, leading to the activation of downstream MA VS. Once activated, MA VS 
activates IRF kinases TBKl and IKK8/t which, in turn, phosphorylate IRF3 and IRF7. 
Phosphorylated IRF3 and IRF7 translocate into the nucleus to stimulate transcription of 
IFNa and IFNJ3 genes by binding to their promoters. 
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IRF7, IRF5 is activated via phosphorylation, after which the activated IRF5 translocates 
to the nucleus to activate transcription of the IFN genes (Malmgaard, 2004). 
Interestingly, IRF5 can also downregulate IFN gene transcription by binding to IRF7, 
thereby preventing IRF7 from binding to the IFN promoters (Barnes et al, 2003). 
1. 2. 2 The TLR -dependent pathway 
Another important discovery in recent IFN research is that activation of TLRs 
leads to the induction of IFNa and IFNJ3. In mammals, there are 11 identified TLRs, of 
which TLR3, 7, 8, and 9 are involved in modulating anti-viral responses (Figure 2) (Akira 
and Takeda, 2005). The TLRs are capable of responding to various viral determinants at 
domains containing leucine rich repeats (LRR). TLR3 recognizes viral dsRNA whereas 
viral single stranded RNA (ssRNA) binds with TLR7 and TLR8, and TLR9 associates 
with unmethylated cytosine-phosphate-guanine (CpG) DNA from DNA viruses (Seth et 
al, 2006). TLRs contain a cytoplasmic toll/IL-l receptor (TIR) domain which functions 
as the docking site for downstream adaptor proteins (Seth et al, 2006). With the 
exception ofTLR3 (whose adaptor protein is TIR-domain-containing adaptor-inducing 
IFN (TRIF)), myeloid differentiation primary response gene 88 (MyD88) serves as an 
adaptor protein for all TLRs to activate downstream TBKI and IKKJ3/i (Takaoka and 
Y anai, 2006). Upon activation, these kinases phosphorylate IRF3 and IRF7 which 
translocate into the nucleus to stimulate IFN gene transcription. 
6 
Figure 2. Induction ofiFNa/p via the TLR-dependent pathway. Products generated 
during viral replication (dsRNA, ssRNA, and CpG) bind to LRR domains ofTLRs. 
TLR3 recognizes viral dsRNA, TLR 7 and TLR8 bind with ssRNA, and TLR9 interacts 
with CpG DNA. Upon recognition of dsRNA, TLR3 activates downstream adaptor 
protein TRIF whereas MyD88 is the downstream target ofTLR7, TLR8, and TLR9. 
Once activated, these adaptor proteins activate TBKl and IKKP/i which phosphorylate 
IRF3 and IRF7 which then translocate into the nucleus and activate transcription of IFNa 
and IFNp. 
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1.3 Jak-STAT signalling pathway 
The Jak-STAT signalling pathway is a well characterized signalling cascade which is 
activated by IFNs and cytokines (Figure 3). IFNa binds to surface receptors IFNAR1 and 
IFNAR2 (Samuel, 2001). This binding leads to heterodimerization of the two receptors 
and subsequent apposition of two tyrosine kinases, Janus kinase 1 ( J ak 1) and tyrosine 
kinase 2 (Tyk2) which are associated with the intracellular domains of IFNAR 
(Kisselvela et al, 2002). After IFN binds with the receptor, Jak1 and Tyk2 phosphorylate 
each other to become activated (Aaronson and Horvath, 2002). Phosphorylated Jak1 and 
Tyk2 phosphorylate downstream transcriptional factors localized within the cytoplasm, 
signal transducer and activator oftranscription 1 (STAT1) and 2 (STAT2) (Darnell et al, 
1994). Phosphorylated STATs dimerize with one another to form a trimeric complex 
termed interferon stimulated gene factor 3 (ISGF3) along with a DNA binding protein 
termed IRF9. ISGF3 then translocates into the nucleus where it binds to specific 
promoter elements ofiFN-inducible genes termed ISRE with the consensus sequence 
AGTTT(N)3TTTC (Aaronson and Horvath, 2002). Binding ofiSGF3 to the ISRE sites 
activates gene transcription ofthe IFN-inducible genes. After gene transcription, the 
STATs become dephosphorylated and are exported back into the cytoplasm to be 
recycled for the Jak-STAT pathway (Kisseleva et al, 2002; McBride et al, 2000). 
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nucleus 
e\ 
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Figure 3. Jak-STAT pathway. IFNa binds to surface receptors IFNARl and IFNAR2 
leading to the activation of receptor associated kinases, Tyk2 and Jakl. Upon activation, 
Jakl and Tyk2 phosphorylate STAT2 and STATl which dimerize and form a trimeric 
complex with IRF9 termed ISGF3. ISGF3 then translocates into the nucleus and binds to 
ISRE sites to activate the transcription ofiFN-inducible genes. 
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Unlike the type I IFN pathway, IFNy binds with IFNy receptor (IFNGR) which 
consists of two subunits IFNGR1 and IFNGR2leading to the activation of Jak1 and Jak2. 
Activated Jak1 and Jak2 phosphorylate cytoplasmic STAT1 which dimerizes and 
translocates to the nucleus. After entering the nucleus, the STAT1 dimer binds at gamma 
activated sites (GAS) of DNA which possess the consensus sequence TTC(N)3-4GAA to 
promote transcription ofiFN-inducible genes. (Aaronson and Horvath, 2002) 
1.4 IFN-inducible anti-viral genes 
Three anti-viral genes induced by IFN include 2'5' -oligoadenylate synthetase (OAS), 
dsRNA-activated protein kinase (PKR), and myxovirus resistance gene (Mx1) (Figure 4) 
(Samuel, 2001 ). Each of these genes contains an ISRE promoter element which can be 
recognized by ISGF3. Studies have shown that in mouse embryonic fibroblasts (MEF) 
with knockouts of latent ribonuclease (RNase L), PKR, and Mx1 are still able to resist 
viral infection in the presence ofiFN, indicating that they are not the only proteins 
responsible for IFN-induced anti-viral defense (Samuel, 2001). Other IFN-inducible 
genes include RNA-specific adenosine deaminase (ADAR), inducible nitric oxide 
synthase (iNOS), and MHC proteins all of which inhibit different stages of the viral 
replicative cycle. ADAR inhibits viral infection by editing viral RNA transcripts 
(Samuel, 2001 ). Nitric oxide produced from iN OS mediates the killing of cells infected 
by a virus (Michel and Feron, 1997). MHC proteins contribute to anti-viral defense by 
presenting viral antigens to T cells (Biron, 1998). 
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of RNA translation nucleus 
Figure 4. IFN-induced anti-viral proteins. Upon recognition of viral dsRNA in the 
cytoplasm, OAS synthesizes 2'-5'-oligoadenylates which activate the ribonuclease RNase 
L, leading to degradation of viral and host RNA. After binding with viral dsRNA, PKR 
becomes activated via autophosphorylation. Activated PKR phosphorylates eiF2a, 
resulting in inhibition of translation. Mx inhibits viral replication by blocking transport of 
viral nucleocapsid into the nucleus. 
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1.4.1 OASIRNase L 
OAS is a cytoplasmic enzyme which is activated by viral dsRNA (Samuel, 2001 ). 
dsRNA is a product ofthe replicative cycle of RNA viruses. dsRNA is also produced by 
the annealing of complementary RNA strands transcribed from some DNA viruses 
(Boone et al, 1979). Upon activation by dsRNA, OAS catalyzes the formation of2-5A 
oligoadenylates (Kerr, 1987; Stark et al, 1998). The 2-5A oligoadenylate molecules then 
bind with the dormant ribonuclease RNase L. RNase L activity is dependent on the 
amount of2-5A molecules produced (Li et al, 1998). Low levels of2-5A results in 
selective degradation of viral mRNA whereas a higher level leads to cleavage of 18S and 
28S ribosomal RNA (Li eta!, 1998; Wreschner, 1981). 
RNase Lis an endonuclease which is constitutively expressed in most types of 
cells (Floyd-Smith and Denton, 1981). In its inactive form, RNase Lis a monomer 
without endonuclease activity. Upon binding with 2-5A oligomers, RNase L dimerizes to 
become active. Activated RNase L cleaves both host and viral RNAs on the 3' side of the 
UpXp sequences (Floyd-Smith et al, 1981; Wreschner et al, 1981). The degradation of 
RNA results in suppression of both host and viral mRNA translation, leading to an 
inhibition of viral replication. 
1.4.2 PKR/e!F2a 
PKR is ubiquitously expressed and its expression can be further induced by IFN (Stark et 
· al, 1998). Prior to IFN stimulation, PKR is predominantly localized to the cytoplasm 
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where it associates with ribosomes, with lower amounts localized within the nucleus 
(Thomis et al, 1992). After IFN stimulation, PKR levels in the cytoplasm increase 
whereas levels in the nucleus remain stable (Jeffery et al, 1995). During viral infection, 
PKR is activated by dsRNA generated from the process of viral replication (Kerr, 1987; 
Stark et al, 1998). PKR can associate with dsRNA duplexes ranging in length from 11 bp 
to an optimal size of 80 bp (Bevilacqua and Cech, 1996). Upon binding with dsRNA, 
PKR becomes activated through autophosphorylation (Samuel, 2001). Activated PKR 
catalyzes the addition of a phosphate group to the translation factor eukaryotic initiation 
factor 2a (eiF2a) (Samuel, 1979). 
eiF2a is a subunit of larger complex eiF2. eiF2 contains three subunits a, p, and 
y and functions in association with guanosine triphosphate (GTP) and methionyl-tRNA, 
forming the 43s preinitiation complex along with the 40s ribosomal subunit (Samuel, 
2001). Once mRNA and the 60S subunits bind with the eiF2 complex, GTP is 
hydrolyzed to guanosine diphosphate (GDP). For translation to continue, GDP must be 
converted back to GTP by a reaction which is catalyzed by guanine nucleotide exchange 
factor (GEF) eiF2B. However, when the eiF2a subunit of eiF2 complex is 
phosphorylated, recycling of GDP to GTP by eiF2B is inhibited, which results in a 
translational block. Therefore, the phosphorylation of eiF2a by PKR induces 
translational blocks ofboth host and viral mRNA (Samuel, 2001). 
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1.4.3 Mx 
The Mx proteins belong to a family of dynamin-like GTPases (Horisberger, 1992). The 
two different Mx proteins (Mx1 and Mx2) are localized to different regions of the cell 
with Mx1 residing in the nucleus and Mx2 within the cytosol (MacMicking, 2004). The 
anti-viral mechanisms ofMx are not clearly understood. There is evidence to suggest that 
Mx may be involved in inhibiting transport of viruses across the nuclear membrane 
(Haller et al, 1998; Pavlovic et al, 1993; Weber et al, 2000). Viruses which replicate 
within the nucleus, such as orthomyxoviruses and thogaviruses, are sensitive to Mx1 
activity whereas cytosolic viruses such as bunyaviruses are susceptible to the effects of 
Mx2 (Haller and Koch, 2000). 
1.5 Therapeutic strategies for IFNa 
IFNa has been proven useful for the treatment of both viral diseases and different types of 
cancers. IFNa is widely used for treatment of hepatitis Band C virus (Mazzella et al, 
1999; Pianko and Mchutchinson, 2000). IFNa has also been approved as a treatment for 
genital herpes caused by herpes simplex virus (HSV) (Ophir et al, 1995) and for 
rhinovirus (Gwaltney et al, 2002). 
In addition to anti-viral activity, IFNa also exhibits potent anti-tumor activity 
(Gutterman, 1994). Cancers that are treated with IFNa include chronic myelogenous 
leukemia (Talpaz et al, 1987) and melanoma (Kirkwood et al, 2002). 
Unfortunately, IFN therapy is not a completely effective form oftherapy. For the 
treatment of chronic hepatitis C, patients given IFN treatment have a response rate of 54-
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63% (Manns et al, 2001, Fried et al, 2002; Hadziyannis et al, 2004). Also, patients with 
high risk melanoma have also demonstrated resistance to IFN therapy (Fluck et al, 2005). 
In this study, the 2-year and 5-year relapse-free survival rates of patients treated with 
IFNa were 48% and 36% respectively. Identification of the mechanisms underlying IFN 
resistance is an important endeavor in developing more effective forms of therapy for 
patients. 
1.6 Molecular negative regulation of IFN-induced responses 
Prolonged activation ofiFN-induced responses can have potent cytotoxic effects, leading 
to the development of asthma, cancer, and immunodeficiency (Schindler, 2002). 
Inhibition ofiFN-induced responses involves three major families of negative regulators 
which are either constitutively expressed or are induced. These include src-homology 2 
(SH2)-containing phosphatases (SHP), suppressors of cytokine signalling (SOCS), and 
protein inhibitor of activated STAT (PIAS) (Wormald and Hilton, 2004). Ras/Raf/MEK 
signalling pathway, which has been studied in our laboratory, is also involved in negative 
regulation of IFN-induced responses. 
1.6.1 SHP 
Two tyrosine phosphatases which have been implicated in the inhibition ofiFN-induced 
responses include SHPl and SHP2. Unlike SHP2 which is ubiquitously expressed, SHPl 
is mainly expressed within hematopoietic cells but has also been detected in epithelial or 
smooth muscle cells (Banville et al, 1995; Valentino and Pierre, 2005). Both 
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phosphatases are constitutively expressed and predominately localized within the 
cytoplasm (Valentino and Pierre, 2005). Both SHP1 and SHP2 contain two N-terminal 
SH2 domains and a C-terminal protein-tyrosine phosphatase domain (Jones et al, 2004). 
The SH2 domains recognize phospho-tyrosine residues present on activated receptor 
associated kinases such as the Jaks. Deactivation ofthe Jaks leads to a loss of 
phosphorylation of STAT proteins, which in turn leads to decreased formation ofiSGF3 
and reduced transcription ofiFN-inducible genes (Shuai and Liu, 2003). 
SHP1 has been shown to negatively regulate the IFNa stimulated Jak/STAT 
pathway in vivo by selectively inactivating Jak1 (David et al, 1995). Another study 
demonstrated that IFNa-induced activation of Jak1, but not Tyk2, was enhanced in 
SHP1_1_ macrophages underlying the importance of SHP1 in attenuating Jak activity 
(Costa-Pereira et al, 2002). 
SHP2 serves diverse physiological roles by promoting mitogenic signals while 
also functioning as a negative regulator of IFN-induced growth-inhibitory and apoptotic 
pathways (Wormald and Hilton, 2003). SHP2 has also been implicated as a regulator of 
the Jak-STAT pathway. In SHP2_1_ mouse embryonic fibroblasts (MEF), phosphorylation 
levels ofSTATl were increased in response to IFNa treatment when compared to wild-
type cells suggesting that activation of STAT1 is dependent on SHP2 activity (You et al, 
1999). A more recent study has shown that protein kinase C (PKC) and SHP2-dependent 
pathway inhibits IFNa-induced Jak-STAT signalling (Du et al, 2005). 
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1.6.2 sacs 
The SOCS family consists of 8 members: the cytokine-inducible SH2 domain-containing 
protein (CIS) and SOCS1 through SOCS7 (Shuai and Liu, 2003). Unlike the SHP and 
PIAS families which are constitutively expressed, expression of SOCS is induced by IFN 
Valentino and Pierre, 2005). sacs family members possess a central SH2 domain that is 
flanked by a variable length amino-terminal domain and a novel conserved carboxyl-
terminal motiftermed the sacs box (Starr and Hilton, 1998). Within the SOCS family, 
CIS, SOCS1, SaCS2, and SaCS3 have been shown to attenuate Jak-STAT pathway 
signalling (Wormald and Hilton, 2004). sacs members inhibit Jak-STAT signalling by 
either: (1) binding to and inhibiting the activity of Jaks, (2) competing with STATs for 
phosphorylated binding sites on receptors, or (3) targeting bound signalling proteins for 
proteasomal degradation (Kamizono et al, 2001; Kile et al, 2002; Krebs and Hilton, 
2000). Over expression of SOCS 1 and SOCS3 have been shown to inhibit induction of 
aAS and Mx by both IFNa and type III IFNs (Vlotides et al, 2004; Brand eta!, 2005). 
1.6.3 PIAS 
The mammalian PIAS family contains four members: PIAS1, PIAS3, PIASX, and PIASY 
(Shuai, 2000). Each of the PIAS members is capable of disrupting functionality of STAT 
proteins. PIAS 1 and PIASY have been shown to inhibit STAT1-mediated gene activation 
by disrupting its ability to bind with DNA (Liu et al, 1998; Liu et al, 2001). PIASX and 
PIASY disrupt STAT1-dependent transcription without inhibiting the DNA-binding 
capability ofSTAT1 (Arora et al, 2003). The direct interaction between PIAS-STAT 
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occurs only after cytokine stimulation as PIAS proteins are unable to bind monomeric 
forms ofthe STAT proteins (Shaui and Liu, 2003). 
1.6.4 Activated Ras signaling pathways 
Ras is a membrane-bound guanosine triphosphate (GTP)-binding protein which is 
important for the regulation of several biological processes including proliferation, 
transformation, and differentiation (Campbell et al, 1998). Three isoforms ofRas have 
been identified including H-Ras, Ki-Ras, and N-Ras (Yan et al, 1998). Activation ofRas 
leads to the stimulation of a number of cellular signaling pathways. One of the 
downstream targets activated by Ras in a GTP-dependant manner is the serine/threonine 
protein kinase Rafwhich in turn leads to the phosphorylation of mitogen-activated 
protein/extracellular signal-regulated kinase kinase 1 (MEKl) and 2 (MEK2) (Campbell 
et al, 1998). When phosphorylated, MEK1 and MEK2 activate extracellular signal-
regulated kinase 1 (ERK 1) and ERK2, which regulate several transcriptional factors 
including E26 transformation-specific (Ets), Ets-like protein (Elk), and myelocytomatosis 
viral oncogene homolog (c-Myc) (Lewis et al, 1998). 
Activated Ras is a negative regulator of the IFN-induced anti-viral state. When 
BALB/c-3T3 cells were transfected with viral oncogene (v-Ras), induction ofMHC I by 
IFN was inhibited (Offermann and Faller, 1990). Inhibition ofPKR by activated Ras was 
first reported by Mundschau and Faller (Mundschau and Faller, 1992). Activation of K-
Ras suppressed GAS-mediated transcription of IFNy stimulated genes by inhibiting 
18 
expression of STATl/2 (Klampfer et al, 2003). However, the mechanism by which Ras 
suppresses the IFN pathway remains unknown. 
1. 7 Mechanisms underlying abrogation of IFN-induced responses by activated Ras 
Studies conducted in this laboratory have demonstrated that activation of the 
Ras/Raf/MEK pathway suppresses IFN-induced anti-viral responses (Battcock et al, 
2006). In this study, it was found that cells with activated Ras were not protected from 
viral infection by IFNa whereas the control cells containing normal Ras were protected 
by IFNa (Figure 6). IFN sensitivity ofRas activated cells was restored upon knockdown 
of downstream MEK with RNA interference (RNAi). Expression ofPKR in IFN-
stimulated control cells and Ras activated cells was similar suggesting that PKR levels are 
unaffected by activation ofRas/Raf/MEK. It is unknown which elements of the IFNa 
induced anti-viral pathway are targeted by the Ras/Raf/MEK pathway. In this study, we 
hypothesized that activated Ras/Raf/MEK pathway inhibits a component of the IFN 
pathway between activation of Jak-STAT pathway and induction of anti-viral proteins. 
Decreased levels of anti-viral proteins could decrease the ability of cells to resist viral 
infection. To identify the precise mechanism whereby activated Ras/Raf/MEK inhibits 
the IFN-induced anti-viral response, a systematic analysis of the IFN system including 
activation ofiFN-inducible genes and of upstream Jak-STAT pathway was conducted in 
the present study. 
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Figure 5. Activation ofRas suppresses IFN-induced anti-viral response. NIH 3T3 cells were 
transfected with either an empty vector control (BABE) or an vector encoding an activated 
Ras (V12). When challenged with VSV- Vesicular stomatitis virus (VSV) in the absence of 
IFN, both BABE and V 12 were susceptible to infection as high levels of cytopathic effects 
(CPE) were observed. When treated with IFN (500UI/ml) prior to viral challenge, BABE 
was protected from infection as low levels of CPE were observed. Importantly, Vl2 was not 
protected from viral infection as high levels of CPE were observed after viral challenge. 
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1.8 Objective 
The objective of this thesis was to determine which element of the IFN pathway is 
targeted by activated Ras/Raf/MEK 
1.9 Aims 
1) To determine whether activated Ras/Raf/MEK pathway suppresses the induction 
ofPKR, OAS, and Mx by IFN 
2) To determine whether activated Ras/Raf/MEK suppresses activation of the Jak-
ST AT pathway by IFN 
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Chapter 2: Materials and methods 
2.1 Reagents and antibodies 
The following reagents and antibodies were used in this study: IFNa (Sigma, St. Louis, 
MO, cat. no. 18782). U0126 (Calibiochem, La Jolla, CA, cat. no. 662005), anti-phospho-
STAT!, anti-phospho-STAT2, anti-total-STATl and anti-total-STAT2 (Upstate Cell 
Signaling Solutions, Lake Placid, NY cat. no. 07-714,07-224,06-501,06-502 
respectively), anti-p-actin (Sigma, cat. no. A2228), anti-ERK, anti-phospho-ERKl/2 
(Calibiochem, cat. no. 442704, 442706), and anti-OAS (provided by Dr. Y oshihiro 
Sokawa, Kyoto Institute ofTechnology, Kyoto, Japan). 
2.2 Cell culture 
Murine fibroblast cell line, NIH3T3, was obtained from the American Type Culture 
Collection. Bosc23 cells were generously provided by Dr. Patrick Lee (Dalhousie 
University, Halifax, Nova Scotia, Canada). All cell lines utilized in this study were 
maintained in high-glucose Dulbecco's modified medium (DMEM) (Invitrogen, 
Burlington, Ontario, Canada) containing 10% fetal bovine serum (FBS) (Cansera, 
Etobicoke, Ontario, Canada). pBABE retroviral vectors containing activated Ras were 
generously provided by Dr. Patrick Lee (Norman et al, 2004). To generate Ras 
transformed cell lines, the retroviral vectors were transfected into Bosc23 packaging cells 
(provided by Dr. Patrick Lee) using Superfect (Qiagen, Valencia, CA) according to the 
manufacturer's instructions. Following a transfection period of 48 hours, supernatants 
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containing retroviruses were harvested, filtered, and stored at -70 °C. NIH3T3 cells 
infected with retroviruses were selected with 2 Jlg of puromycin/ml for 2 weeks. 
2.3 RNAi 
Two oligonucleotides corresponding to nucleotide sequences of H-Ras were synthesized 
by Invitrogen: 5'-ccacuauagaggauuccuaccggaa-3' [positions 289 to 314] and 5'-
ccuguguguguuugccauaacaac-3' [positions 422 to 446]. Negative control RNAi comprised 
of a random nucleotide sequence was used as a control for non-specific effects due to 
transfection of duplex RNA. Cells were grown to 40% to 50% confluence in 24-well 
plates, washed twice with phosphate buffered saline (PBS), and then incubated with a 
transfection mixture containing DMEM without antibiotics, 10% FBS, RNAi 
Lipofectamine (20 Jlg/ml), and oligonucleotides (final concentration range, 10 to 50 pM). 
Transfection was repeated after 24 hours for greater suppression of the Ras gene. To 
confirm the efficacy of the Ras RNAi on silencing Ras, phosphorylation of downstream 
ERK was assessed by western blot analysis. 
2.4 Northern blot analysis 
2.4.1 Preparation of RNA samples 
Cells were plated in 100 mm X 20 mm tissue culture dishes ( 4 x 106 cells/dish) and were 
incubated at 37 °C until cells were 80% confluent. Following IFN stimulation (500 
U/ml), RNA was extracted from cells with TRizol (Invitrogen) according to the 
manufacturer's directions. RNA concentrations were determined according to the 
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Warburg-Christian method using DU Series 500 spectrophotometer (Beckman 
Instruments, Inc., Fullerton, CA). Experiments and subsequent analyses were repeated (n 
=2) to improve accuracy. Collected RNA samples were used for preparation of 
complementary DNA (eDNA) probes or for northern blot analysis. Samples for northern 
blot analysis were diluted in Northern Max Formaldehyde Load Dye (Ambion), heated at 
60 °C for 10 min, and then stored at -45 °C until needed. 
2.4.2 Preparation of probes 
To construct eDNA probes, the following primers were designed: PKR 5'-
gttaaagagcccgccgaa-3' (forward) and 5'- ttctcatccattgctccaaa-3' (reverse); OAS 5'-
attacctccttcccgacacc-3' (forward) and 5 '-gcatcaggaggtggagtttg-3' (reverse); Mx 5 '-
aaacctgatccgacttcacttcc-3' (forward) and 5'- tcttcttctctctggtgtcactc-3' (reverse); 
glyceraldehyde-3-phosphatase dehydrogenase (GAPDH), 5' -gggtggagccaaacgggtca-3' 
(forward) and 5' -tgcgacttcaacagcaactcc-3' (reverse). 
One microgram of RNA isolated from IFN-stimulated BABE was subjected to 
reverse transcription (R T) using random hexanucleotide primers and reverse transcriptase 
according to the First-Strand eDNA Synthesis Kit (GE Healthcare Bio-Sciences Corp., 
Piscataway, NJ). The cDNAs generated by RT reaction were then subjected to 
polymerase chain reaction (PCR) using specific primers for OAS, Mx, PKR, and GADPH 
in a Mastercycler gradient (Eppendorf, Hamburg, Germany). PCR for each target gene 
were carried out as follows: denaturation at 94 °C for 1 min, annealing at 55 °C for 1 
min, extension at 72 °C for 1 min with 28 cycles used for OAS and PKR and 30 cycles 
used for Mx and GADPH. Final extension was performed at 72 °C for 10 min for each of 
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the target sequences. PCR amplification products were cloned using the TOPO TA 
Cloning Kit (Invitrogen). The cloning reaction was carried out as specified by the 
manufacturers' instructions. Clones were digested using Hind III and Xho restriction 
enzymes (Invitrogen) and subjected to electrophoresis on a 1% agarose gel (Invitrogen) 
containing ethidium bromide (0.4 mg/ml). The PCR product of interest was first 
visualized by 254 nm shortwave UV (Spectroline, Universal X-ray Company of Canada) 
and was then excised from the gel using a gel extraction kit (Qiagen) and then amplified 
using a kit according to the manufacturer's instructions (Qiagen). The prepared probes 
were stored at -20 °C until needed. 
2.4.3 Gel electrophoresis and transfer 
Ten micrograms of each RNA sample were denatured at 60 °C for 10 minutes and then 
fractionated in a 1% agarose gel containing 2.2 M formaldehyde gel and lX 3-(N-
morpholina) propansulfonic acid (MOPS) buffer at lOOV in IX MOPS/0.22M 
formaldehyde running buffer. RNA was transferred overnight to a nylon membrane 
(Hybond-XL; Amersham Biosciences, Little Chalfont, Buckinghamshire, England) by 
upward capillary action using 2X saline sodium citrate (SSC) buffer. RNA was cross-
linked to the membrane using a UVC-508 ultraviolet cross-linker (Ultra-Lum., 
Paramount, CA). Membranes were stored at -20 °C until needed. 
2.4.4 Hybridization 
Membranes were prehybridized in hybridization buffer (Ambion) for 1 hour at 
42 °C in a hybridization oven (Robbins Scientific, Sunnyvale, CA). eDNA probes were 
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labelled with 32P- dCTP (Amersham Biosciences) using a Megaprime DNA Labeling kit 
(Amersham Biosciences) according to the manufacturers instructions. Unincorporated 
nucleotides were removed using a Nick column containing G50 Sephadex (Amersham 
Biosciences). Hybridizations were performed overnight at 42 °C. After the 
hybridization, membranes were washed twice for 5 minutes each at 42 °C with 2X SSC 
and 0.1% SDS followed by washing twice at 42 °C with 0.2X SSC and 0.1% SDS for 15 
minutes each. The membranes were exposed to Kodak BioMax XAR scientific imaging 
film which was then developed using a Konica SRX-101A Medical Film Processor. The 
membranes with weak signals were exposed to Cyclone Storage Phosphor Screens 
(Perkin Elmer Life Sciences, Boston, MA) and analyzed using a Cyclone Storage 
Phosphor System (Packard) and using an Epson Perfection 3170 Photo Scanner (Seiko 
Epson Corporation, Japan). Quantifications of band intensities were performed using 
Kodak Molecular Imaging Software (Eastern Kodak Company, Rochester, NY). 
2.5 Western blot analysis 
2.5.1 Preparation of protein samples 
Cells were plated in 6 or 24 well plates with 4 x 106 cells/well or 4 x 104 cells/well 
respectively. Following IFN stimulation (500 U/ml), the cells were lysed in 
radioimmunoprecipitation assay (RIP A) buffer, PBS containing 1% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS with 10 ~-tg/ml aprotinin, 100 ~-tg/ml 
phenylmethylsulponyafluoride (PMSF) and 1% phosphatase inhibitor cocktail (Sigma). 
After 3 minutes cooling on ice, protein samples were cleared of debris by centrifugation 
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at 12,000x g for 3 minutes. Protein concentrations in samples were determined by the 
bicinchoninic acid (BCA) method (BCA Protein Assay Kit, Pierce Biotechnology, Inc., 
Rockford, IL) or the Bradford method (Bio-Rad) using a Beckman DU Series 500 
spectrophotometer (Beckman Instruments, Inc.). Experiments and subsequent analyses 
were repeated (n = 2) in order to improve accuracy. Following protein determination, the 
protein samples were boiled at 100 °C for 5 min in 3X bromophenol blue (3X BPB). The 
samples were stored at -45 °C until needed. 
2.5.2 Gel electrophoresis and transfer 
Protein samples were subjected to 8% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 1 OOV for 2 hours and transferred to nitrocellulose 
membrane at lOOv for 1 hour (Bio-Rad, Mississauga, Ontario, Canada). A protein ladder 
containing bands ranging from 10-200 kDa (Benchmark Prestained Protein Ladder) was 
loaded to assess the molecular weight of the target proteins. 
2.5.3 Immunoblotting 
Membranes were blocked with 5% skim milk in Tris-buffered saline (TBS) (20 mM Tris 
and 137 mM NaCl [pH 7.3]) containing 0.1% Tween 20 for 20 minutes prior to 
incubation with primary antibodies. Dilutions for primary antibodies were prepared as 
recommended by provider (Table 1 ). All primary antibody incubations were performed 
overnight at 4°C with shaking. After washing, the membrane was incubated with 
peroxidase-conjugated goat anti-rabbit immunoglobulin (IgG) or anti-mouse IgG (1 :5000 
to 1 :10000) (Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature, and 
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Table 1 Primary antibody dilutions for Western blot analysis 
Antibody Dilution 
Anti-phospho-STAT1 1:2000 
Anti-phospho-STAT2 1:2000 
Anti-STAT1 1:2000 
Anti-STAT2 1:2000 
Anti-phospho-ERK 1:5000 
Anti-ERK 1:5000 
Anti-actin 1:10000 
Anti-OAS 1:50 
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specific bands were detected with the SuperSignal West Pico Chemiluminescent detection 
kit (Pierce Biotechnology, Inc., Rockford, IL). Bands were visualized on Kodak BioMax 
XAR scientific imaging film (Eastman Kodak Company, Rochester). The film was 
developed using a Konica SRX-101A Medical Film Processor (Konica Medical and 
Graphic Corporation, Japan), and then scanned onto a computer using an Epson 
Perfection 3170 Photo Scanner (Seiko Epson Corporation, Japan). 
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Chapter 3: Results 
3.1 Activation of Ras/RapMEK suppresses transcription of IFN-inducible genes 
To determine the effect of activated Ras on anti-viral genes induced by IFN, Ras 
activated NIH 3T3 cells (RasV12) and vector control NIH 3T3 cells (BABE) were grown 
to 80% confluency and then treated with IFNa (500 U/ml) for 6 and 12 hours or left 
untreated (time 0). At each time point, the cells were lysed and RNA was extracted for 
Northern blot analysis to identify expression ofiFN-induced anti-viral genes, OAS, Mx, 
and PKR, and a housekeeping gene GAPDH (Figure 6A). In the absence of IFN 
stimulation, there was no detectable expression of any of these anti-viral genes. At 6 and 
12 hours following IFN treatment, induction ofOAS, Mx, and PKR mRNA was observed 
in both BABE and RasV12. Importantly, expression levels of these genes were higher in 
BABE at both 6 and 12 hours after IFN treatment when compared to RasV12. This was 
confirmed using densitometry analysis (Figure 6B). Thus, Northern blot analysis revealed 
that activation ofRas/Raf/MEK suppresses induction of anti-viral genes by IFN. 
3.2 Restoration of induction of IFN-inducible genes in Ras activated cells 
From the previous experiment, activated Ras suppressed transcription ofiFN-inducible 
genes. To determine whether induction ofiFN-inducible genes by IFN was restored by 
suppression ofRas/Raf/MEK, Northern blot analysis was conducted on RasV12 
pretreated with an MEK inhibitor (U0126) prior to IFN stimulation. RasV12 were 
pretreated with U0126 for 16 hours prior to IFN treatment. At time 0, BABE, RasV12, 
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Figure 6. Activation ofRas suppresses induction ofiFN-inducible genes. (A) Vector 
control cells (B) and RasV12 cells (V) were incubated with or without IFNa (500 U/ml) 
for 6 and 12 hours. RNA was extracted using TRizol reagent followed by Northern blot 
analysis for OAS, Mx, PKR, and GAPDH transcription. (B) Densitometry analysis. 
Values were reported as the ratio ofOAS/GADPH, Mx/GADPH, and PKR/GADPH. 
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and U0126 treated RasV12 cells were stimulated with IFNa (500 U/ml). RNA samples 
were obtained at 0 and 12 hours following the IFN treatment and analyzed by Northern 
blotting (Figure 7A). As observed in Figure 7A, OAS and Mx genes were not transcribed 
in the absence of the IFN treatment in BABE or RasV12 cells. As well, there was no 
apparent induction ofthe IFN-inducible genes in U0126 treated RasV12 before the IFN 
stimulation. After 12 hours ofiFN stimulation, induction ofOAS and Mx mRNA were 
observed in BABE, RasV12, and U0126 pretreated RasV12. Induction of the IFN-
inducible genes by IFN was higher in BABE than in RasV12. Importantly, when RasV12 
were pretreated with U0126 prior to IFN treatment, induction ofthe IFN-inducible genes 
by IFN was restored. This was further confirmed using densitometry analysis (Figure 
7B). 
In summary, suppression ofiFN-inducible genes by activated Ras can be reversed 
when the cells are treated with a MEK inhibitor prior to IFN stimulation. These results 
suggest that activation of MEK inhibits induction of anti-viral genes by IFN. 
3. 3 Inhibition of activated Ras/Raj!MEK pathway restores induction of OAS protein levels 
To further confirm that activation ofRas/Raf/MEK inhibits transcription ofiFN-inducible 
genes, it was investigated whether different temporal expression patterns of OAS protein 
occurred between BABE and RasV12 following IFN stimulation. BABE and RasV12 
were treated with IFNa (500 U/ml) for 24 hours followed by Western blot analysis using 
antibodies against OAS, phosphorylated ERK (p-ERK), and total ERK (t-ERK) (Figure 
8). 
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Figure 7. Inhibition of activated Ras/Raf/MEK pathways restores induction of IFN-
inducible genes in RasV12. RasV12 were incubated with or without U0126 16 hr prior to 
IFNa treatment. Vector control cells (B), RasV12 (V), and U0126 pretreated RasV12 (V 
U0126) were stimulated with or without IFNa (500 U/ml) for 12 hours. RNA samples 
were obtained using TRizol reagent followed by Northern blot analysis for OAS, Mx, and 
GAPDH. (B) Densitometry analysis. Values are reported as ratio ofOAS/GAPDH and 
Mx/GAPDH. 
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Figure 8. Inhibition of activated Ras/Raf/MEK pathway restores induction of OAS 
protein. (A) BABE (lane 1) and RasV12 (lane 2). RasV12 pretreated with U0126 (lane 3) 
or without U0126 (lane 4) 16hours prior to IFNa treatment. Ras-specific oligonucleotide 
sequence (RasRNAi) (lane 5) or random sequence (NGRNAi) were transfected to 
RasV12 (lane 6) twice during a 24 hour interval. All cells were incubated with IFNa 
(500 U/ml) for 24 hours followed by cell lysis and Western blot analysis with antibodies 
against OAS, phosphorylated ERK, and total ERK. (B) Densitometry analysis. Values 
are reported as ratio of OAS/ERK. 
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Phosphorylation levels of ERK were analyzed to assess activity of the Ras/Raf/MEK 
pathway whereas total levels of ERK were used as the protein loading control. At 24 
hours after IFN stimulation, induction of OAS protein was observed in BABE (Figure 8, 
lane 1) whereas induction ofOAS was lower in RasV12 (Figure 8, lane 2). Western blot 
analysis revealed that RasV12 cells displayed higher levels of phosphorylated ERK than 
BABE cells, indicating greater levels ofRas/Raf/MEK activity in RasV12 cells. This was 
confirmed using densitometry analysis (Figure 8B) 
In an attempt to rescue induction ofOAS protein by IFN, RasV12 were pretreated 
with U0126 for 16 hours prior to IFN stimulation (Figure 8, lane 3) or were treated with 
U0126 at the same time as IFN stimulation (Figure 8, lane 4). In the pretreatment group, 
the induction of OAS was restored to levels comparable with that of BABE (Figure 8, 
lane 1) whereas, in the non-pretreatment group (Figure 8, lane 4), expression levels of 
OAS protein were increased but not as efficiently as observed in the pretreatment group. 
Levels of phosphorylated ERK were reduced by U0126 treatment suggesting that 
upstream MEK was inhibited. 
To further demonstrate the restoration of OAS proteins levels by suppression of 
activated Ras, RasV12 were pretreated with Ras-specific oligonucleotide sequence 
(RasRNAi) or random sequence RNAi (NGRNAi) prior to IFN treatment (Figure 8, lane 
5 and 6). Efficacy of the RasRNAi inhibition was confirmed since low levels of 
phosphorylated ERK were detected when compared to RasV12. RasRNAi treatment 
restored induction ofOAS protein by IFN in RasV12 cells to levels comparable with that 
in BABE cells. However, NGRNAi treatment did not affect levels of phosphorylated 
ERK and failed to restore the induction of OAS. This experiment clearly indicated that 
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induction of OAS protein by IFN can be rescued in cells with activated Ras by disruption 
of Ras/Raf/MEK signaling. 
3.4 Activation of Ras/Raj!MEK suppresses activation of the Jak-STAT pathway 
The suppression ofiFN-inducible genes by the Ras/Raf!MEK pathway could be the result 
of down-regulation of upstream Jak-STAT signaling. Therefore, activation status of the 
Jak-STAT pathway in BABE and RasV12 cells stimulated with IFN was determined 
(Figure 9). After 0.5, 1, and 2 hours following IFN treatment, proteins samples were 
prepared from BABE and RasV12 for Western blotting and analyzed using antibodies 
against phosphorylated STAT1, phosphorylated STAT2, total STAT1, total STAT2 and 
total ERK. In the absence ofiFN treatment (time 0), there was no observable 
phosphorylation ofSTAT1 and STAT2 in BABE and RasV12. At 0.5, 1, and 2 hours of 
IFN treatment, phosphorylation levels ofSTAT1 and STAT2 were higher in BABE than 
in RasV12. Before and after IFN treatment, lower amounts of total STAT1 and STAT2 
were detected in RasV12 than in BABE. 
These results suggested that there were two possible mechanisms of how activated 
Ras suppresses the Jak-STAT pathway. First, activated Ras might inhibit cytoplasmic 
levels ofSTAT1 and STAT2leading to reduced activation ofthe STAT proteins. 
Second, regardless of lower cytoplasmic availability, Ras activation may suppress the 
Jak-STAT pathway by inhibiting activity ofkinases upstream ofSTATl and STAT2 
including Jak1 and Tyk2 and/or reducing levels ofiFNAR. Nonetheless, it was 
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Figure 9. Activated Ras/Raf/MEK pathway inhibits activation of the JAK-STAT 
pathway. BABE (B) and RasV12 (V) were incubated with or without IFNa (500 U/ml) 
for 0, 0.5, 1 and 2 hours. Cellular proteins were harvested with RIP A buffer followed by 
Western blot analysis using antibodies against phosphorylated STATl (p-STATl), total 
STATl (t-STATl), phosphorylated STAT2 (p-STAT2), total STAT (t-STAT2) and total 
ERK (t-ERK). 
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concluded that inhibition of transcription ofiFN-inducible genes is due to suppression of 
the Jak-STAT pathway by activated Ras. 
3.5 Inhibition of activated Ras/Raj!MEK pathway restores activation of the Jak-STAT 
pathway 
Upon observation that activated Ras pathway inhibited total and phosphorylated STATl 
and STAT2levels, it was decided to determine whether the inhibition of the 
Ras/Raf/MEK pathway could rescue activation of the Jak-STAT pathway. RasV12 were 
pretreated with U0126 for 16 hours prior to IFN stimulation. At time 0, BABE, RasV12, 
and RasV12 with U0126 pretreatment were treated with IFNa for 0.5 hours (Figure 10, 
time 0). Western blot analysis was conducted using antibodies against phosphorylated 
STATl, phosphorylated STAT2, total STATl, total STAT2 and 13-actin. In the absence 
of IFN, there was no phosphorylation of STATl or STAT2 in BABE in all cells tested 
(Figure 10, time 0). The total levels ofSTATl and STAT2 were reduced in RasV12 
compared to those in BABE. However, treatment ofRasV12 with U0126 restored levels 
of both total STATl and total STAT2. Treatment with IFN for 0.5 hours led to greater 
phosphorylation levels ofSTATl and STAT2 in BABE compared to RasV12 while 
phosphorylation levels ofSTATl and STAT2 in RasV12 pretreated with U0126 were 
restored. 
In summary, activation ofthe Jak-STAT pathway was restored when activated 
MEK was inhibited. This indicated that MEK and its downstream elements were 
responsible for interruption of the Jak-STAT pathway. 
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Figure 10. Inhibition ofthe Ras/Raf/MEK pathway restores activation ofthe Jak-STAT 
pathway in response to IFN. RasV12 (V) were incubated with or without U0126 16 hours 
prior to IFNa treatment. BABE (B), RasV12 (V), and U0126 pretreated RasV12 
(V U0126) were incubated with or without IFNa (500 U/ml) for 0.5 hours. Proteins were 
harvested using RIP A buffer followed by Western blot analysis using antibodies against 
phospho phosphorylated STATl (p-STAT1), total STATl (t-STAT1), phosphorylated 
STAT2 (p-STAT2), total STAT (t-STAT2) and f3-actin. 
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Chapter 4: Discussion 
4.1 Suppression of the IFN-induced anti-viral response 
The IFN system is an important first line of defense restricting viral replication. Intact 
Jak-STAT signalling is vital for maintaining robust induction ofiFN-induced anti-viral 
genes. Several studies have demonstrated that disruption of Jak-STAT signalling leads to 
resistance to IFN (Landolfo, 2000; Wong, 1997). Some viruses containing genes that 
encode anti-IFN proteins can evade the IFN system by interrupting the Jak-STAT 
pathway (Young et al, 2002; Dideock et al, 1999). However IFN-sensitive viruses such 
as VSV, may selectively replicate within cells that are resistant to IFN due to high 
activities of negative regulators against the IFN-induced anti-viral response (Obuchi et al, 
2003). Previous work from this laboratory demonstrated that activated Ras/Raf/MEK 
suppresses the IFN-induced anti-viral response (Battcock et al, 2006). As activation of the 
Ras/Raf/MEK pathway defines cellular sensitivity to IFN, the objective this masters 
project was to determine the molecular mechanisms underlying suppression of the IFN-
induced response by the Ras/Raf/MEK pathway_ To do this, a step-by-step analysis was 
performed to compare activation of the IFN pathway between Ras activated cells and 
vector control cells. 
4.2 Summary of key findings 
1) Activation ofRas/Raf/MEK downregulated expression ofiFN-inducible genes. 
2) Lower levels of cytoplasmic STATl and STAT2 occurred in cells with activated 
Ras/Raf/MEK. 
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3) Diminished induction of STAT1 and STAT2 phosphorylation by IFN occurred in 
cells with activated Ras/Raf/MEK. 
4.2.1 Inhibition of IFN-inducible genes by activated Ras 
Activation ofRas reduced IFN-induced transcription ofOAS, Mx, and PKR genes 
(Figure 6). However, the degree of the inhibition observed was not equal among the three 
genes. OAS mRNA expression was clearly suppressed to a greater extent than the other 
genes. A possible explanation for the differential influence of activated Ras is the 
variation of promoter regions regulating transcription ofthese genes. IFN-inducible 
genes are transcribed upon binding of ISGF3 to the ISRE promoter site (Samuel, 2001 ). 
Since ISRE for OAS, Mx, and PKR genes varies in sequence and number within the 
promoters, they may compete for association with ISGF3 under insufficient activation of 
the STATs in RasV12 cells (Geiss et al, 2003; Kuhen and Samuel, 1997; Darnell et al, 
1994). Although the mechanisms behind ISRE selectivity are not fully understood, the 
ISRE within the OAS promoter may have the weakest affinity for ISGF3 based on 
features of its sequence. Therefore, the Mx and PKR ISREs may out-compete the OAS 
ISRE promoter for binding with ISGF3, thereby leading to greater inhibition of 
transcription of the OAS gene. 
Previously in this laboratory, Western blot analysis using anti-PKR antibody 
revealed that activation ofRas/Raf/MEK did not affect induction ofiFN-induced PKR 
protein (Battcock et al, 2006). Contrary to this finding, Northern blot analysis in the 
present study showed that activated Ras inhibited induction of PKR mRNA by IFN 
(Figure 6). The inconsistency between the two studies is most likely due to the difference 
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in the stability of the targets (i.e., PKR mRNA and PKR protein), detected by Western 
blot and Northern blot analysis. For example, in the previous study western blot analysis 
detected PKR protein in the absence of IFN treatment, while PKR mRNA was not 
detected in IFN untreated controls in the current study. Overall, Northern blot analysis 
appears to give a more accurate measure of expression of PKR because it detects newly 
synthesized mRNA. 
4.2.2 Inhibition of the Jak-STAT pathway by activated Ras 
In this study, we found that the STAT pathway was inhibited by activated Ras. We 
propose two possible mechanisms of how the downregulation of the STAT pathway may 
occur: (1) Disruption ofupstream signaling impairing phosphorylation ofSTATl and 
STAT2 regardless of cytoplasmic STAT availability and (2) Insufficient availability of 
cytoplasmic STAT proteins leading to decreased phosphorylation ofboth STAT! and 
STAT2. In either case, reduced levels of phosphorylated STAT! and STAT2 would lead 
to decreased formation ofiSGF3, thereby resulting in reduced transcription of anti-viral 
genes (Figure 11 ). However, it still remains to be explained precisely how Ras disrupts 
the functionality of the STAT pathway. 
4.2.3 Disruption of upstream signaling by activated Ras/Raj!MEK pathway 
Numbers ofiFN receptors displayed on the cell surface can limit activation ofthe Jak-
STAT pathway (Muller et al, 1994). A possibility is that activated Ras decreases levels 
ofiFNAR, thereby impairing downstream signaling. However, based on a review of the 
literature, there is no clear evidence that activated Ras reduces cell surface levels of 
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Figure 11. Possible mechanisms underlying suppression of IFN-inducible genes by 
activated Ras/Raf/MEK pathway. Activation ofRas/Raf/MEK inhibits Jak-STAT 
pathway signaling by inhibiting phosphorylation of the STAT proteins. Decreased 
phosphorylated-STAT levels could be the result of impaired upstream function or 
decreased cytoplasmic availability of STATs. This in turn results in decreased levels of 
ISGF3 and inhibition of IFN-inducible genes. A decreased level of anti-viral proteins 
leads to a weakened anti-viral response. 
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IFNAR. In a related study, activation ofKi-Ras did not affect levels ofiFNy receptor, 
suggesting that Ras is unable to target the IFN response at the receptor level (Klampfer et 
al, 2003). 
Decreased phosphorylation of STAT 1 and S T AT2 could result from suppression 
of upstream kinases Jak1 and Tyk2 which are targeted by negative regulators within the 
cell. Negative regulators of Jak1 and Tyk2 include members of the SHP and SOCS 
protein families (Starr and Hilton, 1998). Jak1 has been shown to be dephosphorylated 
by SHP1 (David et al, 1995). It is also known that SHP1 can promote degradation of 
both Jak1 and Tyk2 (Wu et al, 2003). SOCS 1 and SOCS3 can disrupt normal activity of 
the Jak kinases (Wormald and Hilton, 2004). Interestingly, research conducted in this 
laboratory has found that activation ofRas promotes transcription of the SHP1 and 
SOCS3 gene upon IFN stimulation (Battcock unpublished, 2006). Therefore, it is also 
possible that the inhibition of the Jak-STAT pathway in cells with activated Ras is due to 
increased expression of negative regulators, such as SHP1 and SOCS3, which leads to 
impaired function of Jak1 and Tyk2. 
4.2.4 Inhibition ofSTAT levels by activation ofRas/Raj!MEK 
Insufficient availability of cytoplasmic STAT1 and STAT2 may also attribute to their 
decreased phosphorylation. To transmit signals from upstream to downstream 
components of the Jak-STAT pathway, a certain amount of STAT proteins must be 
present within the cytoplasm (Darnell et al, 1994). The amount of cytoplasmic STAT 
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proteins is regulated by the following mechanisms: (1) transcription, (2) degradation, and 
(3) translocation. 
The major inducer of STAT gene transcription is IFN (Samuel, 2001). Basal level 
expression of STAT1 and STAT2 genes is regulated by circulation of endogenous IFN. 
IFN binds to cognate surface receptors that activate the Jak-STAT pathway which in turn 
stimulates ISRE-mediated gene transcription ofthe STAT genes (Darnell, 1994). It is 
possible that downregulation of interferon regulatory factors (IRFs) by activated Ras 
would lead to insufficient production of endogenous IFN for maintaining the basal levels 
of STAT proteins within cytoplasm. 
Increased degradation of the STAT proteins is another possible mechanism 
underlying decreased cytoplasmic availability ofSTAT1 and STAT2. Proteosome-
dependent degradation is an important process in terms of reduction of the STATs 
(Hendry and John, 2004). Indeed, some viruses such as mumps virus or paramyxovirus 
promote proteosome-mediated destruction of STAT1 and STAT2 as a means of evading 
the IFN anti-viral system (Young et al, 2002; Dideock et al, 1999). As well, there is some 
evidence to suggest that the SOCS1 is involved in ubiquitination of STAT proteins 
(Wormald and Hilton, 2004). Promotion ofproteosome-dependent degradation activity 
· by activated Ras could result in reduced levels of STATl and STAT2 in the cytoplasm. 
Dysfunction of mechanisms controlling translocation may also result in low levels 
of cytoplasmic STATs. Upon phosphorylation by upstream kinases Jakl and Tyk2, 
STAT1 and STAT2 dimerize and subsequently bind with IRF9 to form ISGF3. This 
trimeric complex translocates into the nucleus and binds with ISRE sequences to activate 
IFN-inducible gene transcription (see Figure 3). Following this event, STATs are 
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dephosphorylated by nuclear phosphatases and are exported out into the cytoplasm where 
they are recycled into the Jak-STAT pathway (Haspel and Darnell, 1999). Transport of 
STAT proteins out of the nucleus is a tightly regulated process involving multiple cellular 
components (O'Shea et al, 2002). Accumulation of STAT1 and STAT2 in the nucleus is 
modulated by nuclear export via a Ras-related protein termed Ran (McBride et al, 2000). 
Ran-dependent interaction with chromosome region maintenance (CRM)1/exportin 1 
regulates transport ofSTATs across the nucleus (McBride et al, 2000). Import ofSTATs 
into the nucleus is controlled by a nuclear import receptor, importina5 and Ran (O'Shea 
et al, 2002). Although a review of the literature did not suggest any direct connection 
between Ras and exportin activity, it may be possible that the Ras/Raf/MEK pathway has 
a yet to be identified role in the modulation of exportin activity. Inhibition of exportin by 
Ras would result in an accumulation ofSTAT1 and STAT2 in the nucleus and thus 
explain the reduced cytoplasmic levels of these proteins in Ras activated cells. 
4.3 Clinical implications - cancer 
Defining the mechanism of cell resistance to IFN is critical for improving IFN-based 
cancer therapies. Therapeutic effects of IFN become limited when tumor cells display 
resistance to IFN treatment (Talpaz et al, 1991). Several studies have implicated 
attenuated Jak-STAT signaling as a possible cause of cancer cell resistance to IFN 
(Landolfo et a/2000; Pansky et al, 2000; Wong et al, 1997). Tumor cells are often 
resistant to the anti-proliferative effects of IFN due to the high activity of negative 
regulators targeting the IFN pathway. Ras/Raf/MEK pathway has been shown to be 
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constitutively active in a number of cancer cells (Scholl et al, 2005). If the Ras/Raf/MEK 
pathway underlies the resistance to IFN treatment in human cancer cells, a new treatment 
for cancer patients may be a combined therapy with IFN and chemical inhibitors against 
the Ras/Raf/MEK pathway. In future, in vitro experiments will be required to test the 
effectiveness of those inhibitors on suppression of tumor cell growth by IFN. As well, it 
will be necessary to conduct in vivo experiments to determine the efficacy of the 
combined therapy. 
4.4 Clinical implications- virus infection 
Resistance of cells infected with viruses to IFN is also an issue when treating virally 
infected patients. Viruses have evolved a wide plethora of strategies to evade the IFN 
system, such as releasing proteins that directly disrupt the IFN pathway (Grandvaux et al, 
2002; Levy et al, 2001 ). Other mechanisms include manipulation of cellular signaling 
pathways that suppress the IFN-induced anti-viral response. They may also selectively 
replicate within cells insensitive to IFN due to activated negative regulators of IFN 
(Basler and Garcia-Sastra, 2002). However, it is still not clear that why the IFN therapy 
becomes ineffective in certain virally infected patients. Therefore, it is important to study 
the basis of cellular resistance to IFN in order to improve the effectiveness of IFN therapy 
for virus infection. Numerous studies have demonstrated the upregulation of Ras by 
viruses during infection. The Raf/MEK/ERK pathway is activated by Coxsackie virus 
during infection by inducing cleavage ofp21GTPase-activating protein (RasGAP) (Huber 
et al, 1999). Boma disease virus activates the Raf/MEK/ERK pathway which is 
necessary for spreading to neighbouring cells (Planz et al, 2001). In the current study, it 
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was determined that activated Ras/Raf/MEK impairs normal Jak-STAT signaling which 
abrogates IFN-induced anti-viral responses. With this new insight, novel drugs could be 
designed to enhance the IFN's anti-viral ability by suppressing negative regulators ofiFN 
within cells. 
4.5 Conclusion 
Previously, this laboratory has shown that activation ofRas suppresses IFN-induced anti-
viral responses. However, the mechanism underlying this suppression was not clear. In 
this project, the objective was to determine the molecular basis of how Ras disrupted the 
IFN pathway. Based on evidence presented in this thesis, it is now better understood that 
activated Ras suppresses STAT signalling which leads to impaired transcription ofiFN-
inducible genes. This loss ofiFN-inducible gene expression ultimately results in an 
abrogated anti-viral response. Identification of the precise mechanisms underlying 
suppression ofiFN-induced responses by activated Ras/Raf/MEK pathway has important 
clinical applications in terms of improving IFN therapy for cancer and virally infected 
patients. 
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